Professional Documents
Culture Documents
Journal of Cardiovascular
Pharmacology and Therapeutics
2016, Vol. 21(3) 233-244
The Author(s) 2015
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1074248415598321
cpt.sagepub.com
Abstract
Background: Published clinical practice guidelines have addressed antihypertensive therapy and sexual dysfunction (SD) in many
different ways. Objective: In this systematic review, we evaluated guidelines that address antihypertensive drug-associated SD,
guideline recommendations, and recent guideline trends. Methods: Thirty sets of guidelines for hypertension management in
adults that had been published in the English language since 2000 were reviewed. The primary outcome measure was
antihypertensive-associated SD potential, which was independently evaluated using specific questions by 2 authors in a nonblinded
standardized manner. Results: Sexual dysfunctions associated with thiazide-class diuretics, b-blockers, and centrally acting
sympathoplegics were addressed by half of the guidelines reviewed. There is no clarity on b-blockers and thiazide-class diuretics
because one-third of the guidelines are vague about individual b-blockers and diuretics, and there is no statement on thirdgeneration b-blockers and thiazide-like diuretics that can improve erectile function. The revised guidelines never use terms
such as loss of libido, ejaculatory dysfunction, lack of orgasm, and priapism. Summary versions of guidelines are inadequate to
reflect the key interpretation of the primary guidelines on SD associated with antihypertensives, even in the major guidelines that
were updated recently. Therapeutic issues such as exploring SD in clinical history, assessing SD prior to and during treatment with
antihypertensives, substituting the offending agents with alternatives that possess a better safety profile, intervening with
phosphodiesterase-5 inhibitors, and avoiding the concomitant use of nitrovasodilators are superficially addressed by most
guidelines, with the exception of 2013 European Society of Hypertension/European Society of Cardiology and Seventh Joint
National Committee recommendations. Conclusion: Future guideline revisions, including both full and summary reports, should
provide a balanced perspective on antihypertensive-related SD issues to improve the impact of hypertension treatment guidelines
on patient care and quality of life.
Keywords
hypertension, guidelines, antihypertensive drugs, sexual dysfunctions, treatment, revisions, adult male
Introduction
Cardiovascular disease is the leading cause of death, and public health efforts to improve lifestyles and risk factors can
contribute to cardiovascular disease prevention.1 Despite the
significant progress made in improving drug therapies for
hypertension and the promulgation of treatment guidelines
over the past 2 decades, only a small proportion of patients
with documented hypertension have had their condition controlled to target levels. Moreover, the complex interrelationship among hypertension, erectile dysfunction (ED), and
antihypertensive drug therapy has become better understood
in recent years. Erectile dysfunction has a high prevalence
in individuals with multiple cardiovascular risk factors and
patients with cardiovascular diseases.2-4 Hypertension is considered one of the most hazardous risk factors and is a frequent comorbidity in men with ED.5 The prevalence of ED
234
Most of the recently revised guidelines for managing hypertension in adults, both comprehensive and abridged versions,
do not satisfactorily address the complexity of hypertension
and sexual dysfunction (SD).17-21 Only a minority of clinical
practice guidelines stress the importance of ED or other
sexual-related issues either as adverse outcomes or as factors
to be considered when making treatment decisions.22
The purpose of this systematic review is to critically evaluate how comprehensively ED associated with antihypertensive
drug therapy is addressed by various national and international
guidelines that were developed for managing arterial hypertension in adults, with reference to (1) recognizing antihypertensive drug-associated SD; (2) the potential differences in the
guideline recommendations that were presented as complete
or summary versions of international reports; and (3) comparisons between the guideline recommendations published at the
end of the second millennium and those developed at the beginning of the third millennium.
Methods
The general methodology (literature search, inclusion/exclusion criteria, outcome measures, validity assessment, and definitions) used in this review has been described previously.22,23
1.
2.
3.
4.
5.
6.
7.
Validity Assessment
Literature Search
National and international guidelines for hypertension management were identified by searching for the following PubMed
Medical Subject Heading terms: guidelines and hypertension. The World Wide Web via Google search engine and
other effective search approaches were used with the following
title: Guidelines on management of hypertension followed by
name of countries (eg, Bahrain and Taiwan) or organizations
(eg, National Institute for Health and Clinical Excellence
[NICE], European Society of Hypertension [ESH], and
National Heart, Lung, and Blood Institute [NHLBI]). The
search was limited to studies that were published from January 2000 through January 2014. Based on the contact details
retrieved from the International Society of Hypertension
(ISH) Web site, e-mails were sent to several ISH-affiliated
societies of Middle East, South East Asia, and Africa and
requested these societies to provide the Web sites of their
national guidelines for the management of arterial hypertension in adults, if available, in English.
Outcome Measures
The primary outcome measures were the potential antihypertensives associated with SD. The guidelines were evaluated
with research questions adapted from Karavitakis et al.22
Operational Definitions
In the tables, the guidelines recommendations pertaining to the
adverse effects of antihypertensives on sexual function in male
patients are identified as () if they are available or addressed
and as () if they are not available or not addressed. A superficially addressed guideline (SAG) means that data pertaining to
hypertension- and antihypertensive-related ED were primarily
derived from tables that list compelling and possible indications,
contraindications, and cautions for major classes of antihypertensive drugs. A comprehensively addressed guideline (CAG)
means that hypertension and antihypertensive-induced SD as a
category has been explicitly addressed as one of the various
headings under hypertension in special patient groups.
Results
A total of 30 national and international guidelines fulfilled
the inclusion criteria used in this review for outcome measures,
as summarized in Table 1. The recommendations related to
the antihypertensive-associated SD (thiazide-class diuretics,
b-blockers, and centrally acting sympathoplegics) were not
addressed in 46.7% (14 of 30), superficially addressed in
43.3% (13 of 30), and comprehensively addressed in 10%
(3 of 30) of the reviewed guidelines. Thiazide-class diuretics
235
SAG
NA
NA
SAG
SAG
NA
SAG
NA
NA
NA
SAG
NA
SAG
SAG
CAG
CAG
NA
NA
SAG
NA
SAG
SAG
SAG
NA
NA
SAG
NA
CAG
NA
SAG
GHA
MOH, Bahrain
MOH, Malaysia
MOH, Singapore
SHMS
TSC
KSC
TFCPP-HK
HF
LASH
PAHO/CHRC
BHS
ESH
ESH/ESC
NICE
SIGN
ASH/ISH
WHO/ISH
WHO
AACE
ACCF/AHA
CCS
DVA/DoD
ICSI
ISHIB
NHLBI
NHLBI
RNAO
Guidelines
Presentation
EHS
SAHS
Acronym
2006
2011
2011
2004
2010
2010
2003
2014
2005
2014
2003
2007
2004
2009
2013
2011
2007
2009
2007
2008
2010
2008
2008
2005
2011
2010
2006
2010
2004
2011
Year
c,I
a,ED
d
c,ED
d
a,ED
a,ED
h,SD
i,I
k,SD
c,ED
a,SD
a,ED
26
34
35
37
38
40
47
46
45
44
43
42
21
41
39
20
19
18
16
15
36
33
32
31
30
29
28
27
25
a,I
Diuretics
24
Ref #
a,ED,j
a,SD,f
c,ED,NS
a,ED,NS
a,ED,j
a,SD,NS
i,I,NS
a,ED,NS
a,ED,f
h,SD,f
c,ED,NS
c,I,NS
a,ED,NS
a,I,NS
b-Blockers
a,g,ED
g,i,SD
a,g,ED
g,h,SD
a,e,I
a,b,I
CASDs
Predictable Antihypertensives
Associated With Sexual Dysfunction
Abbreviations: CAG, comprehensively addressed guideline; CASDs, centrally acting sympathoplegic drugs; NA, not addressed; SAG, superficially addressed guideline; , data are available; , no data are
available; ED, erectile dysfunction; I, impotence; NS, not specified; SD, sexual dysfunction; S, specified.
a
Side effect/adverse effect.
b
Clonidine methyldopa.
c
Potential adverse effect.
d
Possible contraindication in sexually active males.
e
Methyldopa.
f
More prominent with old generations and not with new one such as nebivolol.
g
Nonspecified drug.
h
Adverse effects were more prominent with old antihypertensive drugs, however in 2009 Guidelines15 old antihypertensives were defined as diuretics, b-blockers, and centrally acting drugs.
i
Major adverse effects.
j
Old generations of b-blockers.
k
Spironolactone.
Africa
Egyptian Hypertension Society
Southern African Hypertension Society
Asia
Gulf Heart Association
Ministry of Health, Bahrain
Ministry of Health, Malaysia
Ministry of Health, Singapore
Saudi Hypertension Management Society
Taiwan Society of Cardiology
The Korean Society of Circulation
The Task Force on Conceptual and Preventive Protocols (Hong Kong)
Australia
Heart Foundation
Caribbean and Latin America
Latin America Society of Hypertension
Pan America Health Organization/Caribbean Health Research Council
Europe
British Hypertension Society
European Society of Hypertension-reappraisal
European Society of Hypertension/European Society of Cardiology
National Institute of Health and Clinical Excellence (United Kingdom)
Scottish Intercollegiate Guidelines Network
International
American Society of Hypertension/International Society of Hypertension
World Health Organization/International Society of Hypertension
World Health Organization
North America
American Association of Clinical Endocrinologist Hypertension Task Force
American College of Cardiology Foundation/American Heart Association
Canadian Cardiovascular Society
Dept of Veterans Administration/Dept of Defense (United States)
Institute of Clinical Systems Improvement (United States)
International Society on Hypertension in Blacks
National Heart, Lung, Blood Institute (United States)
National Heart, Lung, Blood Institute (United States)
Registered Nurses Association of Ontario
Organizations
Table 1. Antihypertensives With Predictable Sexual Dysfunction Addressed by National and International Guidelines.
236
Organizations
(Publication Year)
BHS-IV (2004)
HF (2008)
NHLBI (2003)
WHO (2007)
Full Report
Summary Version48
Full Report34
Quick Reference Guide49
Full Report, 200345
JNC-7 Express, 200350
Full Report39
Pocket Guidelines51
Guidelines
Presentation
SAG
NA
SAG
NA
CAG
NA
SAG
NA
Antihypertensive-Induced
Sexual Dysfunction
No. of Pages
46
7
38
18
48
12
92
20
Diuretics
a,ED
b,ED
a,SD
d,I
b-Blockers
CASDs
a,ED,NS
b,ED,NS
a,ED,NS
d,I,NS
a,c,ED
c,d,SD
Abbreviations: CAG, comprehensively addressed guideline; CASDs, centrally acting sympathoplegic drugs; NA, not addressed; SAG, superficially addressed
guideline; , data are available; , no data are available; ED, erectile dysfunction; I, impotence; NS, not specified; SD, sexual dysfunction; BHS-IV, 2004 Fourth
Working Party of British Hypertension Society; HF, Heart Foundation; NHLBI, National Heart, Lung, Blood Institute; WHO, World Health Organization.
a
Side effect/adverse effect.
b
Potential adverse effect.
c
Nonspecified drug.
d
Major adverse effects.
Organizations
(Reference #)
Publication
Year
Guideline
Presentation
Diuretics
b-Blockers
CASDs
BHS-III52
BHS-IV37
NHLBI-VI53
NHLBI-VII45
WHO/ISH54
WHO/ISH20
1999
2004
1997
2003
1999
2003
NA
SAG
NA
CAG
SAG
NA
a,ED
a,SD
a,I
a,ED,NS
a,ED,NS
a,b,ED
Abbreviations: CAG, comprehensively addressed guideline; CASDs, centrally acting sympathoplegic drugs; NA, not addressed; SAG, superficially addressed
guideline; , data are available; , no data are available; ED, erectile dysfunction; I, impotence; NS, not specified; SD, sexual dysfunction; BHS, Working Party of
British Hypertension Society; NHLBI, National Heart, Lung, Blood Institute; WHO, World Health Organization; ISH, International Society of Hypertension.
a
Side effect/adverse effect.
b
Nonspecified drug.
Al Khaja et al
237
Year
Ref #
Q1
Q2
Q3
Q4
Q5
2004
2011
24
2010
2008
2008
2005
2011
2010
2006
2010
26
2008
34
2009
2006
35
2004
2009
2013
2011
2007
37
2014
2003
2007
38
2006
2011
2011
2004
2010
2010
2004
2014
2005
40
25
27
28
29
30
31
32
33
36
15
16
18
19
20
39
41
21
42
43
44
45
46
47
Q6
Q7
c
c
30
10
53.3
10
10
6.7
0
Discussion
Thiazide-class diuretics are one of the most widely used
class of antihypertensives. They are used both as fixed-dose
formulations and as individual agents in complementary
238
Al Khaja et al
239
240
Conclusion
In this systematic review, there may be a discrimination bias
because only English-language guidelines were included in the
analysis. Notwithstanding this limitation, hypertension treatment guidelines have placed less emphasis on the issue of antihypertensive drug-associated SD. Most of the national or
international guidelines are less explicit concerning preexisting
or treatment-induced SD in patients with hypertension, with the
exception of the 2003 NHLBI, 2009 ESH and the more recently
revised 2013 ESH/ESC guidelines. The future guideline revisions, including both full and summary report versions, should
provide a balanced perspective on antihypertensive-related SD
issues to improve the QOL of patients with hypertension, bearing in mind that QOL is a more serious issue than hypertension
for many men during midlife.
Acknowledgments
We acknowledge the assistance given to us by Ina DSouza in preparing this manuscript.
Authors Contribution
K. A. J. Al Khaja contributed to conception and design; acquisition,
analysis, and interpretation; drafted the manuscript; critically revised
the manuscript; gave final approval; and agrees to be accountable for
all aspects of work ensuring integrity and accuracy. R. P. Sequeira, A.
K. Alkhaja contributed to acquisition, analysis, and interpretation; critically revised the manuscript; gave final approval; and agree to be
accountable for all aspects of work ensuring integrity and accuracy.
A. H. H. Damanhori contributed to analysis and interpretation, critically revised the manuscript, gave final approval, and agrees to be
accountable for all aspects of work ensuring integrity and accuracy.
Authors Note
This article has not been submitted or presented elsewhere. In preparing this manuscript, the authors have not received financial support
from any drug companies or organizations.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
References
1. Santulli G. Epidemiology of cardiovascular disease in the 21st
century: updated numbers and updated facts. J Cardiovasc Dis.
2013;1(1):1-2.
Al Khaja et al
241
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
242
33. Hong Kong reference framework for hypertension care for adults
in primary care settings; 2010. Web site. http://www.pco.gov.hk/
english/resource/professionals_hypertension_pdf.html. Accessed
August 30, 2015.
34. Heart Foundation. Guide to management of hypertension 2008.
Assessing and managing raised blood pressure in adults. Web site.
http://www.heartfoundation.org.au/SiteCollectionDocuments/
HypertensionGuidelines2008to2010Update.pdf.
Accessed
August 30, 2015.
35. Sanchez RA, Ayala M, Baglivo H, et al. Latin American Guidelines on Hypertension. J Hypertens. 2009;27(5):905-922.
36. Pan American Health Organization. Managing hypertension in
primary care in the Caribbean; 2007. Web site. http://car
pha.org/Portals/0/docs/Clinical%20Guidelines/Hypertension%
20Guidelines.pdf. Accessed August 30, 2015.
37. Williams B, Poulter NR, Brown MJ, et al. The BHS guidelines
working party for the British Hypertension Society. Guidelines
for management of hypertension: report of the fourth working
party of the British Hypertension Society, 2004BHS IV. J Hum
Hypertens. 2004;18(3):139-185.
38. Weber MA, Schiffrin EL, White WB, et al. Clinical practice
guidelines for the management of hypertension on the community. A statement by the American Society of Hypertension and
the International Society of Hypertension. J Clin Hypertens
(Greenwick). 2014;16(1):14-26. doi:10.1111/jch.122237.
39. 2007 World Health Organization. Prevention of cardiovascular
diseases. Guidelines for assessment and management of cardiovascular risk; 2007. Web site. http://www.who.int/cardiovascu
lar_diseases/guidelines/Full%20text.pdf. Accessed August 30,
2015.
40. Torre JJ, Bloomgarden ZT, Dickey RA, et al. AACE Guidelines.
American Association of Clinical Endocrinologists Medical
Guidelines for Clinical Practice for the Diagnosis and Treatment
of Hypertension. AACE Hypertension Task Force. Endocr Pract.
2006;12(2):193-222.
41. ACCF/AHA 2011 Expert consensus document on hypertension in
the elderly. A report of the American College of Cardiology
Foundation Task Force on Clinical Expert Consensus document.
Circulation. 2011;123:2434-2506.
42. Veteran Administration/Department of Defense (VA/DoD) clinical practice guidelines for diagnosis and management of hypertension in the primary care setting. Department of Veteran
Administration/Department of Defense. Update version 2.ob.
2004. Web site. http://www.healthquality.va.gov/hypertension/
htn04_pdf1.pdf. Accessed August 30, 2015.
43. Institute for Clinical Systems Improvement (ICSI) Health Care
Guidelines. Hypertension, Diagnosis and Treatment. 13th ed.
Bloomington, MN: Institute for Clinical Systems Improvement;
2010. Web site. https://www.icsi.org/_asset/wjqy4g/HTN.pdf.
Accessed August 30, 2015.
44. Flack JM, Sica DA, Bakris G, et al. Management of high blood
pressure in blacks. An update of the international society of
Hypertension in blacks consensus statement. Hypertension.
2010;56(5):780-800.
45. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
Al Khaja et al
243
57. Prisant LM, Carr AA, Bottini PB, Solursh DS, Solursh LP. Sexual
dysfunction with antihypertensive drugs. Arch Intern Med. 1994;
154(7):730-736.
58. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects
on sexual function of five antihypertensive drugs and nutritional
hygienic treatment in hypertensive men and women. Treatment
of Mild Hypertension Study (TOMHS). Hypertension. 1997;
29(1 pt 1):8-14.
59. Nicolai MPJ, Liem SS, Both S, et al. A review of the positive and
negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J. 2014;22(1):
11-19.
60. Michel T, Hoffman BB. Treatment of myocardial ischemia and
hypertension. In: Brunton LL, Chabner BA, Knollman BC, eds.
Goodman & Gilmans The Pharmacological Basis of Therapeutics. China: McGraw Hill Medical; 2011:746-788.
61. Saigitov RT, Glezer MG. Effect of arterial hypertension on sexual
health of men and their quality of life. Results of BOLERO study.
Kardiologiia. 2009;49(9):44-50.
62. Lacourciere Y. Analysis of well-being and 24-hour blood pressure
recording in a comparative study between indapamide and captopril. Am J Med. 1988;84(1B):47-52.
63. Werning C, Weitz T, Ludwig B. Assessment of indapamide in
elderly hypertensive patients with special emphasis on wellbeing. Am J Med. 1988;84(1B):104-108.
64. Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS.
Indapamide: a review of its pharmacodynamic properties and
therapeutic efficacy in hypertension. Drugs. 1984;28(3):
189-235.
65. Westfall TC, Westfall DP. Adrenergic agonists and antagonists.
In: Brunton LL, Chabner BA, Knollman BC, eds. Goodman &
Gilmans The Pharmacological Basis of Therapeutics. China,
McGraw Hill Medical: 2011; 277-333.
66. Croog SH, Levine S, Sudilovsky A, Baume RM, Clive J. Sexual
symptoms in hypertensive patients. Arch Intern Med. 1998;
148(4):788-794.
67. Medical Research Council Working Party on mild to moderate
hypertension. Report of 1981. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet. 1981;2(8246):539-543.
68. Freis Ed. Current status of diuretics, b-blockers, a-blockers and
a-b blockers in the treatment of hypertension. Essent Hypertens.
1997;81(6):1305-1317.
69. Mann KV, Abott EC, Gray JD, Thiebaux HJ, Belzer EG. Sexual
dysfunction with beta-blocker therapy: more common than we
think. Sex Disab. 1982;5(2):67-77.
70. Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. The fifth report of the
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;
153(2):154-183.
71. Weber M. The role of the new b-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(12 pt 2):169S-176S.
72. Doumas M, Tsakiris A, Doumas S, et al. Beneficial effects of
switching from beta-blockers to nebivolol on the erectile function
of hypertensive patients. Asian J Androl. 2006;8(2):177-182.
244
89. Fogari R, Zoppi A, Preti P. Sexual activity and plasma testosterone levels in hypertensive males. Am J Hypertens. 2002;15(3):
217-221.
90. Torkler S, Wallaschofski H, Baumeister SE, et al. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male. 2011;14(3):176-182.
91. Agarwal SK. Low testosterone levels in male patients with hypertension. Disease. 2013;2(3):15-18.
92. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri
A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):
5462-5468.
93. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH,
van der Schouw YT. Testosterone sex hormone binding globulin and the metabolic syndrome: a systematic review and metaanalysis of observational studies. Int J Epidemiol. 2011;40(1):
189-207.
94. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil
in hypogondal men with erectile dysfunction who do not respond
to sildenafil alone. J Urol. 2004;172(2):658-663.
95. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE-5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone
96.
97.
98.
99.
100.
101.
102.